Stonepine Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Stonepine Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-159,598	Closed	-$8.57M	–	22
2022 Q3	$8.57M	Sell	159,598 -1,093	-0.7%	-$64.3K	3.85%	9
2022 Q2	$8.94M	Buy	160,691 +42,550	+36%	+$2.41M	4.16%	10
2022 Q1	$8.29M	Buy	+118,141	New	+$8.57M	3.44%	12
2021 Q1	–	Sell	-522,738	Closed	-$32.4M	–	32
2020 Q4	$32.4M	Buy	522,738 +7,373	+1%	+$420K	24.83%	1
2020 Q3	$30.6M	Buy	515,365 +367,237	+248%	+$25.1M	31.88%	1
2020 Q2	$10.3M	Sell	148,128 -109,825	-43%	-$6.96M	20.02%	2
2020 Q1	$11.7M	Buy	+257,953	New	+$14.6M	12.38%	1
2019 Q4	–	Sell	-48,034	Closed	-$2.98M	–	28
2019 Q3	$2.98M	Sell	48,034 -220,448	-82%	-$13.8M	2.9%	14
2019 Q2	$19.1M	Buy	268,482 +28,032	+12%	+$2.06M	13.16%	1
2019 Q1	$18.9M	Buy	+240,450	New	+$18.2M	10.85%	3

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonepine Capital Management's LGND Position: Q4 2022 in Review

Stonepine Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 159,598 shares — an estimated $8.57M sold.

Stonepine Capital Management first reported a position in LGND in Q1 2019 and held it in 10 quarters. The position peaked at $32.4M in Q4 2020. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

Stonepine Capital Management reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Stonepine Capital Management sold 159,598 Ligand Pharmaceuticals shares in Q4 2022, an estimated $8.57M.
Stonepine Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2019 and held it in 10 quarters.
Stonepine Capital Management's Ligand Pharmaceuticals position peaked at $32.4M in Q4 2020.
198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Stonepine Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.